Floatz logo

Micardis®

Treatment-resistant Schizophrenia

Xiaoduo FanPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Treatment-resistant Schizophrenia cohort.

Asset / SponsorPhaseRating
Olanzapine
Dr. Stavroula Rakitzi
Phase 4BB
Risperdal
Dr. Stavroula Rakitzi
Phase 4BB
AMISULPRIDE
University of California, Los Angeles
Phase 4BB
Clozapine
Dr. Stavroula Rakitzi
Phase 4BB
Dextromethorphan
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BB

View all 23 →

Same molecule, other indications

Micardis® is also rated in:

hypertensive disorderDormant
BB
Indicative ·
71 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BB
Indicative ·
70 / 100
View asset →
schizoaffective disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →